

DETECTION OF AMP C B-LACTAMASE PRODUCING BACTERIA ISOLATED IN
NEONATAL SEPSISDr. Sara Mazhar¹, Dr. Madiha Rani² and Dr. Maryam Zakir*³¹PMDC # 81421-P.²PMDC # 81591-P.³PMDC # 81590-P.

*Corresponding Author: Dr. Maryam Zakir

PMDC # 81590-P.

Article Received on 17/01/2018

Article Revised on 07/02/2018

Article Accepted on 28/02/2018

ABSTRACT

Objective: The objective of this study was to determine the occurrence and antimicrobial profile of AmpC β-lactamase producing bacteria. **Methods:** The study was conducted at The DHQ teaching hospital Sargodha and Allied hospital faisalabad, Pakistan, during September 2016 to June 2017. A total number of 1,914 blood samples of suspected neonatal septicemia were processed. Isolates were identified using Gram's staining, API 20E and API 20NE tests. Gram negative isolates were screened for AmpC β-lactamase production against ceftazidime, cefotaxime and ceftiofur resistance and confirmed by inhibitor based method. **Results:** Total number of 54 (8.49%) Gram positive and 582 (91.5%) Gram negative bacteria were identified. Among Gram negative isolates 141 (22%) were AmpC producers and found to be 100% resistant to co-amoxiclav, ceftiofur, ceftazidime, cefotaxime, cefuroxime, cefixime, ceftriaxone, cefpodoxime, gentamicin, amikacin and aztreonam. Less resistance was observed against cefepime (30.4%), sulbactamcefoperazone (24.8%), piperacillin-tazobactam (10.6%), ciprofloxacin (20.5%) and meropenem (2.1%). All the isolates were found sensitive to imipenem. The patients harbored AmpC β-lactamases were on various interventions in which intravenous line was noted among (51.1%), naso-gastric tube (37.6%), ambu bag (8.5%), endotracheal tube (3.5%), ventilator (2.1%) and surgery (0.7%). **Conclusion:** Extensive use of invasive procedures and third generation cephalosporins should be restricted to avoid the emergence of AmpC beta-lactamases in neonates.

KEYWORDS: AmpC β-lactamase detection, Antimicrobial resistance, Multidrug resistant bacteria, Neonatal sepsis.

INTRODUCTION

Beta-lactamases are the bacterial enzymes produced by a number of bacteria that provide resistance to beta-lactam antibiotics which include penicillins, carbapenems, cephalosporins and monobactams. AmpC beta-lactamases hydrolyze all the broad spectrum cephalosporins such as ceftiofur, cefotaxime, ceftazidime and ceftriaxone.^[1] These enzymes are typically present in Gramnegative bacteria which include *Escherichia coli*, *Klebsiella* species, *Salmonella* species, *Shigella*, *Enterobacter* species, *Citrobacter* species, *Pseudomonas aeruginosa*, *Serratia marcescens*, *Providencia*, *Proteus mirabilis* and *Morganella morganii*.^[2]

There is a lack of standard method for the detection of AmpC beta-lactamases however several different methods are being used for AmpC screening. The three-dimensional test is one of the methods for AmpC

detection in which ceftiofur and ceftazidime or cefotaxime are used as indicator drugs.^[3] Another method known as Inhibitor Based Method, is used for the detection of AmpC beta-lactamases. In this method boronic acid is used as inhibitor of AmpC enzyme.^[4]

The most frequent bacteria causing neonatal sepsis are *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Escherichia coli*, *Enterobacter cloacae*, *Citrobacter diversus*, *Pseudomonas aeruginosa*, *Streptococcus pyogenes* and *Staphylococcus aureus*.^[5] Gram negative bacteria have developed high level of resistance to third-generation cephalosporins. The carbapenems, sulbactam and amikacin are used to treat neonatal sepsis caused by Amp C producing strains but if mutations occur in organisms, they can become resistant to carbapenems as well.^[1] Boronic acid can be used as AmpC beta-lactamase inhibitor.^[4] Multidrug resistance can be avoided by the restricted use of third-generation cephalosporins in neonatal sepsis.^[6]

Major risk factors included indiscriminate use of third generation cephalosporins, prolonged stay in hospital and various invasive procedures. The aim of this study was to determine the frequency of bacteria in neonatal sepsis and to detect the presence of AmpC β -lactamases among them along with their antibiotic resistance pattern.

METHODS

This present study was conducted at Microbiology Department of The DHQ teaching hospital Sargodha and Allied hospital faisalabad, Pakistan, during September 2016 to June 2017. A total number of 1,914 blood samples were processed and the sample collection was consecutive and only one clinical isolate per patient (non-repetitive) was included in the study.

The blood samples collected in the brain heart infusion broth were incubated at 37°C. After a period of incubation the cultures were further processed on Blood and MacConkey agar plates. The bacterial identification was done on the basis of colony morphology, fermentation of lactose, oxidase test, Gram's staining, biochemical tests, API 20E and API 20NE (bioMerieux, France).^[7] Isolates were screened for AmpC β -lactamase production by disc diffusion method as described by Clinical Laboratory Standards Institute (CLSI).^[8]

The isolates resistant to ceftazidime, cefotaxime and ceftazidime-clavulanate (CAZ+CL) and cefotaxime-clavulanate (CTX+CL) were used. CAZ+CL and CTX+CL discs were applied on the inoculated Mueller-Hinton agar plate. Discs containing boronic acid were applied in the center at a 5-10mm distance from ceftazidime-clavulanate and cefotaxime-clavulanate. The isolate was detected as AmpC producer if there was keyhole formation (synergism) between any of the cephalosporin+clavulanate and boronic acid disc (Fig.1).^[9]

Antimicrobial sensitivity testing was performed on Muller Hinton agar (90mm) for each bacterial strain. A suspension of each bacteria was made according to the 0.5 McFarland turbidity standard and swabbed over the surface of Muller Hinton agar. *E. coli* ATCC 25922 and *Klebsiella pneumoniae* ATCC 700603 were used as control strains. The isolates were tested with different antibiotics which included amikacin (30 μ g), aztreonam (30 μ g), cefixime (5 μ g), cefotaxime (30 μ g), amoxicillin-clavulanate (20/10 μ g), cefpodoxime (30 μ g), cefepime (30 μ g), ceftazidime (30 μ g), imipenem (10 μ g), meropenem (10 μ g), ceftazidime (30 μ g), ceftriaxone (30 μ g), gentamicin (10 μ g), sulbactam-cefoperazone (75/30 μ g), piperacillin-tazobactam (100/10 μ g), ciprofloxacin (5 μ g) and cefuroxime (30 μ g). After applying these antibiotics on Muller Hinton agar, plates were incubated overnight at 37°C. After overnight incubation the diameter of each zone of inhibition was

measured according to the CLSI guidelines.^[8] The clinical record of each




Fig. 1: Detection of AmpC β -lactamase using inhibitor based method.

Table I: Distribution of AmpC β -lactamase producing bacteria isolated in neonatal sepsis (n=141).

Bacteria	Frequency (n)	Percentage (%)
<i>Enterobacter cloacae</i>	80	56.7
<i>Enterobacter sakazakii</i>	20	14.2
<i>Escherichia coli</i>	14	9.9
<i>Citrobacter freundii</i>	8	5.7
<i>Klebsiella pneumoniae</i>	8	5.7
<i>Klebsiella oxytoca</i>	4	2.8
<i>Serratia marcescens</i>	3	2.1
<i>Acinetobacter baumannii</i>	2	1.4
<i>Pseudomonas aeruginosa</i>	1	0.7
<i>Aeromonas hydrophila</i>	1	0.7

Patient was reviewed. The clinical data of the patients was noted for the various interventions which included intravenous line, naso-gastric tube, ambu bag, endotracheal tube, ventilator and surgery.

RESULTS

Out of total number of 1,914 blood samples 636 samples showed growth of various bacteria. A total number of 54 (8.49%) Gram positive and 582 (91.5%) Gram negative bacteria were isolated. Among the Gram negative bacteria AmpC betalactamases were detected in 141 (22.0%) isolates. The most frequent AmpC β -lactamase producing bacteria were *Enterobacter cloacae* 80 (56.7%) followed by *Enterobacter sakazakii* 20 (14.2%) and *Escherichia coli* 14 (9.9%). The rest of the AmpC β -lactamase producers were *Klebsiella pneumoniae*.^[8]

Table II: Antibiotic resistance of AmpC beta-lactamase producing bacteria.

Antibiotics	Resistant (n)	Percentage (%)
Co-amoxiclav	141	100
Ceftazidime	141	100
Ceftriaxone	141	100
Cefotaxime	141	100
Cefuroxime	141	100
Cefixime	141	100
Cefpodoxime	141	100
Cefoxitin	140	99.3
Gentamicin	136	96.4
Amikacin	132	93.6
Aztreonam	92	65.2
Cefepime	43	30.4
Sulbactam+ cefoperazone	35	24.8
Ciprofloxacin	29	20.5
Piperacillin+ tazobactam	15	10.6
Meropenem	3	2.1
Imipenem	0	0

(5.7%), *Citrobacter freundii* 8 (5.7%), *Klebsiella oxytoca* 4 (2.8%), *Serratia marcescens* 3 (2.1%), *Acinetobacter baumannii* 2 (1.4%), *Pseudomonas aeruginosa* 1 (0.7%) and *Aeromonas hydrophila* 1 (0.7%) (Table - I).

All of the 141 AmpC producing bacteria were resistant to co-amoxiclav, ceftazidime, cefotaxime, cefuroxime, cefixime, ceftriaxone and cefpodoxime. Resistance rate of AmpC producing bacteria to various other antibiotics have been shown in (Table- II).

The various interventions in hospitalized neonates included intravenous line (IV) 72 (51.1%), naso-gastric (NG) tube 53 (37.6%), ambu bag 12 (8.5%), endotracheal tube (ETT) 5 (3.5%), ventilator 3 (2.1%) and Surgery 1 (0.7%) (Table- III).

DISCUSSION

Neonatal sepsis is one of the main cause of morbidity and mortality among the neonates in Pakistan. Among the positive cultures 582 (91.0%) were Gram negative and 54 (9.0%) were Gram positive isolates. These results are in accordance with other studies where Gram negative bacteria caused sepsis in newborns were high in number 92.8% than Gram positive bacteria 7.2%.^[10] A study reported 80.4% Gram negative bacteria and 20.6% Gram positive bacteria in neonatal sepsis.^[8] Muhammad et al. worked on neonatal sepsis and reported different results but with the high frequency of Gram negative bacteria (54.6%) as compared to Gram positive bacteria (45.4%).^[11] Detection of Amp C beta-lactamases poses a challenge to microbiologists. In the present study Amp C beta-lactamase producing bacteria were 22.0%. In other studies the prevalence of Amp C producing isolates was

26.8%^[12] and 19.61%.^[13] Manchanda and Singh worked on the occurrence of Amp C beta-lactamases from clinical isolates of Gram negative bacteria and reported 20.7% Amp C producing bacteria.^[14] Another study conducted on the detection of Amp C beta-lactamase producing isolates reported 35.5% Amp C producers.^[15]

Table III: Frequency of various interventions among the AmpC β lactamase harbouring neonates.

Interventions	Frequency	Percentage (%)
Intravenous line	72	51.1
Naso gastric tube	53	37.6
Ambu bag	12	8.5
Endotracheal tube	5	3.5
ventilator	3	2.1
Surgery	1	0.7

In the present study *Enterobacter cloacae* and *Enterobacter sakazakii* were most prevalent AmpC producing isolates. It has been studied that resistance emerged more often in *Enterobacter* species against cephalosporins than any other bacteria when treated with broad spectrum cephalosporins.^[1] *Enterobacter* species were the most common nosocomial pathogen among Gram negative bacteria and was the cause of pneumonia in 11% of pneumonia cases.^[16]

All the AmpC producing isolates were found to be resistant to co-amoxiclav, ceftazidime, cefotaxime, cefuroxime, cefixime, ceftriaxone and cefpodoxime. A study conducted for the establishment of antimicrobial resistance pattern of AmpC producing Gram negative bacteria reported resistance to cefoxitin (99.3%), gentamicin (96.4%), amikacin (93.6%), aztreonam (65.2%), cefepime (30.4%) and sulbactam-cefoperazone (24.8%).^[15] A study on AmpC beta-lactamases reported that all the AmpC producers were resistant to cefoxitin and aztreonam.^[11,14] In the present study AmpC producers did not show high resistance to cefepime and sulbactam-cefoperazone which is in accordance with other studies in which AmpC beta-lactamases were observed to be less resistant to cefepime and all the AmpC producers were sensitive to sulbactam-cefoperazone.^[15,17]

In the present study ciprofloxacin resistance was found to be (20.5%) and majority of the isolates were sensitive to this antibiotic which is similar to a study where AmpC producing isolates were also found sensitive (30%) to ciprofloxacin.^[20] In the present study rate of resistance against piperacillintazobactam was 10.6% which is similar to a study in which susceptibility pattern of AmpC producing isolates was determined and they were found to be sensitive to piperacillin-tazobactam (78%).^[18]

In our study resistance against meropenem was observed to be 4.9% and none of the isolate showed resistance to imipenem. It shows that the majority of isolates were

sensitive to carbapenems. Herman and Beatrice, (2005) carried out a study on the antibiotic susceptibility pattern of AmpC betalactamase producing *Enterobacteriaceae* and reported carbapenems as most effective antimicrobial drugs for the infection caused by AmpC producing *Enterobacteria*.^[19] Another study also reported the AmpC producing strains highly sensitive to carbapenems.^[20]

The patients who harboured AmpC betalactamase producing bacteria were on various interventions which included intravenous line (IV), naso-gastric (NG) tube, ambu bag, endotracheal tube (ETT), ventilator support and surgery. Among these interventions, frequency of intravenous line was higher 72 (51.1%) than others. In another study intravenous lines were observed among the risk factors associated with nosocomial bacteremia.^[21] Ambu bags were observed as the source of transmission of pathogenic organism from one patient to another.^[22] The use of ETT is also a cause of microbial colonization due to the formation of biofilms. ETT was considered as the significant cause of development of ventilator associated pneumonia.^[23] A study conducted to detect the correlation of infections with various invasive procedures in different units of hospital. The rate of infection due to ventilator was 0.44 per 1000 ventilator-days and central-line was 4.6 per 1000 catheter-days in the neonatal intensive care unit.^[24] Surgical procedures are also common cause of acquiring the pathogens inside the body. Invasion of pathogens may occur due to use of contaminated apparatus during surgery or handling the surgical wounds with contaminated hands and dressings after surgery. The invasive procedures are associated with sepsis and are the major cause of blood stream infections.^[25]

Neonatal sepsis caused by AmpC beta-lactamase producing bacteria causes treatment failure and high rate of mortality. Meropenem and imipenem can be used for their treatment. Different epidemiological studies should be taken on in hospital settings to monitor the sources of infection. To avoid the complications, minimize the use of unnecessary invasive procedures. Moreover, indiscriminate use of broad spectrum cephalosporins should be restricted in hospital environment and antibiotic policy should be revised time to time to reduce the emergence of AmpC producing bacteria.

ACKNOWLEDGEMENTS

We are thankful to the administration and ethical committees of The DHQ teaching hospital Sargodha and Allied hospital faisalabad, Pakistan for providing us all kind of facilities.

Grant Support & Financial Disclosures: Nothing to declare.

REFERENCES

- Jacoby GA. AmpC β -Lactamases. Clin Microbiol Rev., 2009; 22(1): 161-182. doi: 10.1128/CMR.00036-08.
- Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev., 1995; 8(4): 557-584.
- Poirel L, Naas T, Nicolas D, Collet L, Bellais S, Cavallo JD, et al. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a *Pseudomonas aeruginosa* clinical isolate in France. Antimicrob. Agents Chem other, 2000; 44(4): 891-897. doi: 10.1128/AAC.44.4.891-897.
- Beesley T, Gascoyne N, Knott-Hunziker V, Petursson S, Waley SG, Jaurin B, et al. The inhibition of class C β -lactamases by boronic acids. Biochem. J., 1983; 209(1): 229-233. doi: 10.1042/bj2090229.
- Mahmood A, Karamat KA, Butt T. Neonatal sepsis: high antibiotic resistance of the bacterial pathogens in a neonatal intensive care unit in Karachi. J Pak Med Assoc, 2002; 52(8): 348-350.
- Kaistha N, Mehta M, Singla N, Garg R, Chander J. Neonatal septicemia isolates and resistance patterns in a tertiary care hospital of North India. J. Infect. Dev. Ctries, 2009; 4(1): 55-57. doi: 10.3855/jidc.625.
- Cheesbrough M. District laboratory practice in tropical countries (2) Cambridge University press, United Kingdom, 2000; 124-143.
- Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility tests 20th ed. approved standard, CLSI document M100-S20, Wayne, PA: CLSI, 2010; 30.
- Jacoby GA, Walsh KE, Walker VJ. Identification of extended-spectrum, AmpC, and carbapenem-hydrolyzing betalactamases in *Escherichia coli* and *Klebsiella pneumoniae* by disk tests. J Clin Microbiol, 2006; 44(6): 1971-1976. doi: 10.1128/JCM.00062-06.
- Aletyeb SMH, Khosravi AD, Dehdashtian M, Kompani F, Mortazavi SM, Aramesh MR. Identification of bacterial agents and antimicrobial susceptibility of neonatal sepsis: A 54-month study in a tertiary hospital. Afr J Microbiol, 2011; 5(5): 528-531. doi: 10.5897/AJMR10.224.
- Muhammad Z, Ahmed A, Hayat U, Wazir MS, Rafiyatullah, Waqas H. Neonatal sepsis: causative bacteria and their resistance to antibiotics. J Ayub Med Coll Abbottabad, 2010; 22(4): 33-36.
- Mohamudha PR, Harish BR, Parija SC. AmpC betalactamase among Gram negative clinical isolates from a tertiary hospital, South Asia. Braz. J. Microbiol, 2010; 41: 596602. doi: 10.1590/S1517-83822010000300009.
- Wen-en L, Yuan J, Yin T, Hong-mei W. Emergence of AmpC enzymes and antibiotic resistance in Gram negative bacilli. J. Cent. South. Univ, 2006; 31(1): 134-137.
- Manchanda V, Singh NP, Shamweel A, Eideh HK, Thukral SS. Molecular epidemiology of clinical

- isolates of AmpC producing *Klebsiella pneumoniae*. *Indian J. Med. Microbiol*, 2006; 24(3): 177-181.
15. Akujobi CO, Odu NN, Okorondu SI. Detection of AmpC beta-lactamases in clinical isolates of *Escherichia coli* and *Klebsiella*. *Afr. J. Of Clin. Exper. Micrbiol*, 2012; 13(1): 51-55. doi: 10.4314/ajcem/v13i1.6.
 16. Kaye KH, Fraimow, Abrutyes E. Pathogen resistant to antimicrobial agents: Epidemiology, molecular mechanisms and clinical management. *Infect. Dis. Clin. North Am.*, 2000; 14(2).
 17. Roh KH, Uh Y, Kim J, Kim H, Shin DH, Song W. First outbreak of multidrug resistant *Klebsiella pneumoniae* producing both SHV-12 type extended spectrum betalactamase and DHA-1 type AmpC beta-lactamase at a Korean Hospital. *Yonsei Med J.*, 2008; 49(1): 53-57. doi: 10.3349/ymj.2008.49.1.53.
 18. Luzzaro F, Brigante G, D'Andrea MM, Pini B, Giani T, Mantengoli E, et al. Spread of multidrug-resistant *Proteus mirabilis* isolates producing an AmpC-type betalactamase: epidemiology and clinical management. *Int J Antimicrob Agents*, 2009; 33(4): 328-333. doi: 10.1016/j.ijantimicag.2008.09.007.
 19. Goossens, H, Grabein B. Prevalence and antimicrobial susceptibility data for extended spectrum beta-lactamases and AmpC producing Enterobacteriaceae from the MYSTIC program in Europe and United States (1997-2004). *Diag Microbial Infect Dis.*, 2005; 53(4): 257-264. doi: 10.1016/j.diagmicrobio.2005.10.001.
 20. Upadhyay S, Sen MR, Bhattacharjee A. Presence of different beta-lactamase classes among clinical isolates of *Pseudomonas aeruginosa* expressing AmpC beta-lactamase enzymes. *J Infect Dev Ctries*. 2009;4(4):239-242. doi:10.3855/jidc.497.
 21. Rojo D, Pinedo A, Clavijo E, García-Rodríguez A, García V. Analysis of risk factors associated with nosocomial bacteraemias. *J Hosp Infect*, 1999; 42(2): 135-341. doi: 10.1053/jhin.1998.0543.
 22. Mirza IA, Hussain A, Abbasi SA, Malik N, Satti L, Farwa U. Ambu bag as a source of *Acinetobacter baumannii* outbreak in an intensive care unit. *J Coll Physicians Surg Pak*, 2011; 21(3): 176-178. doi: 03.2011/JCPSP.176178.
 23. Baudry T, Ader F. Non-invasive mechanical ventilation to prevent ICU-acquired infection. *Infect Disord Drug Targets*, 2011; 11(4): 384-348. doi: 10.2174/187152611796504782.
 24. Navoa-Ng JA, Berba R, Galapia YA, Rosenthal VD, Villanueva VD, Tolentino MC, et al. Device-associated infections rates in adult, pediatric, and neonatal intensive care units of hospitals in the Philippines: International Nosocomial Infection Control Consortium (INICC) findings. *Am J Infect Control*, 2011; 39(7): 548-554. doi: 10.1016/j.ajic.2010.10.018.
 25. Horrath, R, Collignon P. Controlling intravascular catheter infections. *Aust. Prescr* 2003. doi: 10.18773/austprescr.2003.029.